Identification of a malignant cell associated antigen recognized by a human monoclonal antibody

Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133

“…Vimentin expression was induced under hypoxic conditions and corresponded to increases in invasive metastatic potential of LNCaP tumor cells [7]. Cell surface expression of the SC5 mAb domain of vimentin was observed for cutaneous T-cell lymphomas [8] and earlier the CLNH11.4 MAb was shown to detect vimentin on the surface of a variety of malignant cells including prostate cancer cells, but not on healthy cells [9-11]. With regard to therapeutic efficacy and targeting, glioma patients showed reduced tumor growth after intravenous treatments with the vimentin-specific antibody CLN-IgG [12].…”

Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab

“…Reference Clone generation [3] Specificity analysis [3,4,9,16,17,25] Effector functions [14][15][16][17][18] Xenograft model [17,41] Antigen characterization [19,42] ent human hybridoma, CLNH11 [3,4]. The general properties of pritumumab antibody are listed in Table 1 with their respective reference.…”

“…Additional properties for pritumumab are outlined in Table 2. Overall, the hybridoma clone [9][10][11] as well as the secreted IgG1 antibody have been well characterized [12,13], the antibody shows ADCC and CDCC activity [14][15][16][17][18], the antigen recognized by pritumumab has been characterized [19][20][21][22], and an anti-paratactic idiotype antibody has been generated to pritumumab and shown to be a useful clinical reagent and an indi- cator of clinical outcome [21][22][23][24]. Drug-conjugates of the antibody also demonstrate effectiveness.…”

“…Drug-conjugates of the antibody also demonstrate effectiveness. Specificity analysis of fresh frozen human tissues has shown that the antigen recognized by pritumumab, altered vimentin, to be restricted to various solid tumors irrespective of the germ layer origin of the tissues [4,19,25]. The antigen is found on cells of ectodermal (brain), endodermal (colon, pancreas), and mesodermal (reproductive) origin.…”

“…Scatchard analysis showed a pritumumab affinity of 4.5 × 10 −7 M with the antigen from U-251MG cells. Sequence analysis of purified antigen showed it to be altered vimentin [19,42]. The reactive epitope is located in the c2 (coil 2 of the central rod) domain of vimentin [42].…”